drugset
drugset / Trial / NCT02298283

Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD

NCT02298283 ↗

Phase 2 Completed 40 enrolled The Lymphoma Academic Research Organisation
NaSingle-groupOpen-labelTreatment

Summary

This study aims to evaluate the efficacy brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin's lymphoma and 18-fluorodeoxyglucose (FDG) -PET positivity after 2 cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine).

Timeline

Start
2015-04
Primary completion
2020-07-09
Completion
2020-07-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Brentuximab Vedotin Monoclonal antibody 1.8 mg/kg Intravenous
Background Bleomycin Unknown 10 mg/m2 Intravenous
Background Cyclophosphamide Other / unclassified 1250 mg/m2 Intravenous
Background Doxorubicin Other / unclassified 35 mg/m2 Intravenous
Background Etoposide Small molecule 200 mg/m2 Intravenous
Background Prednisone Other / unclassified 40 mg/m2 Intravenous
Background Vincristine Small molecule 1.4 mg/m2 Intravenous
Background procarbazine Small molecule 100 mg/m2 Intravenous

Indications

Hodgkins lymphoma